Breaking News

Evotec Acquires Euprotec

May 28, 2014

Establishes Anti-Infectives Platform

Evotec AG has acquired Euprotec Ltd, a UK-based CRO specializing in anti-infective drug discovery services with a portfolio of assays and disease models to support drug discovery and development programs through proof-of-concept.
The acquisition adds capabilities to Evotec's drug discovery platform, including anti-infective screening, early PKPD (Pharmacokinetic/Pharmacodynamic) profiling, a range of disease and efficacy models for characterization of anti-bacterials, anti-fungals and anti-virals, StrainBank, a collection of clinical isolates, and core disease biology expertise in infection.
"Through the acquisition of Euprotec's capabilities and its disease biology know-how in infection, Evotec expands its technological portfolio to offer a complete infrastructure and discovery solutions in the field of infectious diseases," said Dr. Werner Lanthaler, chief executive officer of Evotec AG. "Importantly, we acquire highly innovative approaches, within our core competence along the discovery value chain, to open new therapeutic routes in the major market of infectious diseases. Currently, Evotec has two innovative programmes, TargetPicV and TargetPGB, to develop drugs to treat infectious diseases and with this acquisition we can expand this portfolio."
Dr. Lloyd Payne, chief executive officer and co-founder of Euprotec, added, "We are thrilled to be joining forces with Evotec and combining its leading-edge drug discovery platform with Euprotec's comprehensive infectious disease biology capabilities and expertise. We look forward to an exciting new phase of growth with Evotec, and, most importantly, working with our customers to accelerate the development of new breakthrough anti-infective vaccines and therapies."
blog comments powered by Disqus
  • Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    Setting Health-Based Exposure Limits to Support Pharmaceutical Development and Manufacturing

    B.D. Naumann, P.J. Nigro, U. Bruen, L. Parola, D. Cragin and A. Schatz, Merck & Co., Inc. and Ashland, Inc.||May 5, 2016
    Health-based exposure limits are needed to support risk assessments

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.